636 related articles for article (PubMed ID: 20164282)
1. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
[TBL] [Abstract][Full Text] [Related]
2. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
3. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
[TBL] [Abstract][Full Text] [Related]
5. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.
Azevedo AC; Bizerra FC; da Matta DA; de Almeida LP; Rosas R; Colombo AL
Mycopathologia; 2011 Jun; 171(6):411-6. PubMed ID: 21181497
[TBL] [Abstract][Full Text] [Related]
7. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Rinaldi MG; Barnes R; Hu B; Veselov AV; Tiraboschi N; Nagy E; Gibbs DL
J Clin Microbiol; 2005 Dec; 43(12):5848-59. PubMed ID: 16333066
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
9. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
[TBL] [Abstract][Full Text] [Related]
10. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
11. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ; Jones RN;
J Clin Microbiol; 2003 Jan; 41(1):78-83. PubMed ID: 12517829
[TBL] [Abstract][Full Text] [Related]
13. Use of the BIOMIC Video System to evaluate the susceptibility of clinical yeast isolates to fluconazole and voriconazole by a disk diffusion method.
Dóczi I; Mestyán G; Puskás E; Nikolova R; Barcs I; Nagy E
Acta Microbiol Immunol Hung; 2006 Jun; 53(2):135-44. PubMed ID: 16956125
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
15. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Barton R; Bijie H; Bille J; Chang SC; da Luz Martins M; Duse A; Dzierzanowska D; Ellis D; Finquelievich J; Gould I; Gur D; Hoosen A; Lee K; Mallatova N; Mallie M; Peng NG; Petrikos G; Santiago A; Trupl J; VanDen Abeele AM; Wadula J; Zaidi M;
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):162-71. PubMed ID: 20338711
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
Kronvall G; Karlsson I
J Clin Microbiol; 2001 Apr; 39(4):1422-8. PubMed ID: 11283066
[TBL] [Abstract][Full Text] [Related]
18. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.
Maxwell MJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Diekema DJ; Pfaller MA
J Clin Microbiol; 2003 Mar; 41(3):1087-90. PubMed ID: 12624034
[TBL] [Abstract][Full Text] [Related]
20. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Pfaller MA; Diekema DJ; Jones RN; Sader HS; Fluit AC; Hollis RJ; Messer SA;
J Clin Microbiol; 2001 Sep; 39(9):3254-9. PubMed ID: 11526159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]